Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022)

Summary

Mixed Tumors Selpercatinib RET Trial (MSK, Nat Commun. 2022) is a study catalogued by cBioPortal DataHub under the cancer-type code mixed. EvidenceHelix groups it with multiple or not classified from the title studies.

Study description

Targeted sequencing of Selpercatinib treated RET-driven solid cancers.

Text as published in the source's study metadata.

Citation & PubMed

Ezra Y et al. Nat Commun 2022

Linked PubMed records: PMID 35304457

Source & licence

Metadata from cBioPortal DataHub at e1b75cd25b, available under the ODC Open Database License (ODbL) 1.0. See the Source metadata tab for every field.

Source metadata

Study identifier

mixed_selpercatinib_2020

Short name

Selpercatinib RET Trial (2020)

Source cancer-type code

mixed

Reference genome

not given

Source access groups

not given

Original study

View on cBioPortal

Metadata file

meta_study.txt at e1b75cd25b

Database licence

ODC Open Database License (ODbL) 1.0

Study-level metadata only (title, description, cancer-type code, citation, PubMed ids). No patient, sample, mutation or clinical data, and no publication full text, is included. Individual studies may carry their own terms; follow each study's source links before reusing its data.

Citations

Ezra Y et al. Nat Commun 2022

• PubMed record 35304457 ↗

Citation counts are not part of the source metadata and are not shown.

Related studies

• BRAF Fusions - ARCHER Clinical Sequencing Cohort (MSK, Clin Cancer Res 2024)

  Targeted sequencing of 107 clinical cases via ARCHER to characterize the structure and impact of BRAF fusions on clinical course in a tumor-agnostic approach. This study is part of a broader analysis and is complement…

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• BRAF Fusions - IMPACT Clinical Sequencing Cohort (MSK, Clin Cancer Res 2024)

  Targeted sequencing of 105 clinical cases via MSK-IMPACT to characterize the structure and impact of BRAF fusions on clinical course in a tumor-agnostic approach. This study is part of a broader analysis and is comple…

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cancer Therapy and Clonal Hematopoiesis (MSK, Blood Adv 2023)

  Targeted sequencing of 47,532 patient samples with mixed tumor types and their matched normals to identify clonal hematopoiesis mutations using MSK-IMPACT.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cancer Therapy and Clonal Hematopoiesis (MSK, Clin Cancer Res 2022)

  Clonal hematopoiesis mutations identified in blood samples from patients whose tumor-blood pairs were analyzed using MSK-IMPACT.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cancer Therapy and Clonal Hematopoiesis (MSK, Nat Genet 2020)

  Clonal hematopoiesis mutations identified in blood samples from 24,146 patients whose tumor-blood pairs were analyzed using MSK-IMPACT.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Cerebrospinal Fluid Circulating Tumor DNA (MSK, Acta Neuropathol Commun 2024)

  Targeted sequencing of 1,007 cerebrospinal fluid circulating tumor DNA from patients with central nervous system tumors using MSK-IMPACT and their matched normals.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Mixed cfDNA (MSK, Nature Medicine 2019)

  Targeted sequencing of 248 samples from 124 patients' cfDNA/WBC and tumor/normal pairs.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

• Mixed Tumors - MiMSI Cohort (MSK, Nat Commun 2024)

  Targeted sequencing of 5,033 clinical cases and their matched normals via MSK-IMPACT, with pathologist-confirmed orthogonal MMR IHC data.

  Multiple or not classified from the titleMSK studiesSource code mixedPubMed 1

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.